-transparent.png){kind=logo}
Eighteen patients with non-small cell lung cancer were entered into a phase II protocol of oral 4-demethoxydaunorubicin. All were evaluable for toxicity and 17 for response. The major toxicity was hematologic with eight patients developing an ECOG grade 3 or 4 toxicity. There were no responses to the treatment.
Related Publications
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
August 1986,
Onkologie,
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
January 1988,
Cancer chemotherapy and pharmacology,
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
January 1984,
Investigational new drugs,
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
October 1985,
American journal of clinical oncology,
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
July 1986,
Cancer treatment reports,
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
September 1988,
Investigational new drugs,
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
January 1984,
Investigational new drugs,
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
April 1988,
European journal of cancer & clinical oncology,
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
March 1984,
Cancer treatment reports,
H S Hochster, and
M D Green, and
R H Blum, and
J C Wernz, and
J L Speyer, and
F M Muggia
October 1988,
American journal of clinical oncology,
